Researchers receive CAD 45 million to study new psychosis treatments

Roche’s com­pe­ti­tion in the eye dis­ease space is in­ten­si­fy­ing with Re­gen­eron’s high-dose Eylea and a loom­ing biosim­i­lar chal­lenge, but the Swiss phar­ma said its block­buster

Bris­tol My­ers Squibb is boost­ing brand aware­ness for its hy­per­trophic car­diomy­opa­thy drug Camzyos in a new TV cam­paign. The drug’s first-ever com­mer­cial de­buted this week